-
Study aim
-
To determine the effect of simultaneous topical methylprednisolone and topical bupivacaine administration in the retropharyngeal space on the incidence of dysphagia after ACDF
-
Design
-
A phase 3 single-blind controlled clinical trial will be conducted on 60 patients.
All patients who meet the inclusion criteria will be assigned to either the intervention or control group using a block randomization approach, with the randomization sequence generated through the website https://www.sealedenvelope.com/simple-randomiser/v1/lists.
Accordingly, in the intervention group of 30 patients, a combination of 1 cc (40 mg) methylprednisolone and 10 cc (50 mg) of 0.5% bupivacaine will be administered into the retropharyngeal space after irrigation and before fascial closure.
-
Settings and conduct
-
Patients who are candidates for anterior cervical discectomy and fusion surgery at Shariati Hospital in Tehran will be enrolled and allocated to either the intervention or the control group. The patients will be blinded to their group assignment. Patients in the intervention group will receive an injection of the designated compound into the retropharyngeal space, whereas patients in the control group will not receive the injection
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:
Patients undergoing ACDF (up to 3 levels) between C2 and C7.
Exclusion criteria:
Age <18 or >65 years, oropharyngeal tumors, neurological or psychiatric disorders, acute cervical trauma, substance abuse, prior anterior cervical surgery, and pregnancy.
-
Intervention groups
-
In patients undergoing ACDF surgery, the intervention group will receive a local application of a combination of methylprednisolone and bupivacaine in the retrpharyngeal space, while the control group will not receive this combination.
-
Main outcome variables
-
Postoperative dysphagia severity, postoperative odynophagia severity, and duration of surgery